| Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. | |
| | |
MedLine Citation:
|
PMID: 20594138 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The immunomodulators (6-mercaptopurine, azathioprine and methotrexate) and biologics (infliximab, adalimumab, certolizumab and natalizumab) are medications essential in the management of pediatric inflammatory bowel disease. If properly utilized, these medications can control active disease, reduce corticosteroid exposure, induce remission, and promote normal growth and development. However, these medications also have significant toxicity and increase the risk of infections and lymphoma. This article provides information about the safety and efficacy of these medications in the treatment of children with Crohn's disease and ulcerative colitis. |
| | |
Authors:
|
Athos Bousvaros |
Related Documents
:
|
21808958 - Hand hygiene and infection control survey pre- and peri-h1n1-2009 pandemic: knowledge a... 18825608 - Medical management of early pregnancy failure: how to treat and what to expect. 15985818 - Clinical reactivity to insect stings. 18221548 - Pattern of medical waste management: existing scenario in dhaka city, bangladesh. 21647328 - Medical decision and patient's preference: 'much ethics' and more trust always needed. 17255688 - The art of moving the orbits. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of clinical immunology Volume: 6 ISSN: 1744-8409 ISO Abbreviation: Expert Rev Clin Immunol Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-02 Completed Date: 2010-10-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101271248 Medline TA: Expert Rev Clin Immunol Country: England |
Other Details:
|
Languages: eng Pagination: 659-66 Citation Subset: IM |
Affiliation:
|
Inflammatory Bowel Disease Center, Children's Hospital Boston, MA 02115, USA. athos.bousvaros@childrens.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
6-Mercaptopurine
/
adverse effects,
therapeutic use Antibodies, Monoclonal / adverse effects, therapeutic use* Child Colitis, Ulcerative / drug therapy* Crohn Disease / drug therapy* Humans Immunologic Factors / adverse effects, therapeutic use* Infection / chemically induced Lymphoma / chemically induced Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunologic Factors; 50-44-2/6-Mercaptopurine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inflammatory bowel disease and pregnancy: an update.
Next Document: Nutritional therapy for the treatment of pediatric Crohn's disease.